A new review has been published in Human Vaccines & Immunotherapeutics on the existing literature available on the economic evidence demonstrating the antibiotic resistance (AMR)-related value of vaccines.
Researchers from the University of North Carolina, Chapel Hill, found two modeling studies that provided estimates of AMR-related costs averted by pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness.
No cost-effectiveness studies were found that directly examined the cost-effectiveness of vaccines in slowing the development of AMR. Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.